15 October 2021 - - US-based Amber Specialty Pharmacy will begin dispensing Tavneos (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis), in combination with standard therapy, the company said.

Tavneos is manufactured by California-based ChemoCentryx, Inc., a biopharma company focused primarily on orphan and rare diseases.

ANCA-associated vasculitis is a rare systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels.

This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated.

Through this partnership, Amber Specialty Pharmacy's best-in-class service model will support autoimmune specialists, rheumatologists and patients throughout the country.

Amber Specialty Pharmacy is one of two specialty pharmacies selected by ChemoCentryx to dispense Tavneos as part of a limited distribution network.

Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is in the specialty pharmacy industry with more than 20 years of experience providing specialized care for persons with chronic, complex medical conditions.

Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission and the Accreditation Commission for Health Care.

Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with an additional 20 locations throughout the United States and Puerto Rico. Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.